Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

Oxidation of Protein Tyrosine Phosphatases as a Pharmaceutical Mechanism of Action: A Study Using 4-Hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione

Charlotta Liljebris, Pawel Baranczewski, Eva Björkstrand, Styrbjörn Byström, Bo Lundgren, Agneta Tjernberg, Malin Warolén and Stephen R. James
Journal of Pharmacology and Experimental Therapeutics May 2004, 309 (2) 711-719; DOI: https://doi.org/10.1124/jpet.103.062745
Charlotta Liljebris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pawel Baranczewski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Björkstrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Styrbjörn Byström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Lundgren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agneta Tjernberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malin Warolén
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen R. James
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Growth factor and insulin signal transduction comprise series of protein kinases and protein phosphatases whose combined activities serve to propagate the growth factor signal in a regulated fashion. It was shown previously that such signaling cascades generate hydrogen peroxide inside cells. Recent work has implied that one function of this might be to enhance the feed-forward signal through the reversible oxidation and inhibition of protein tyrosine phosphatases (PTPs). We identified compound 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (BVT.948) as an agent that is able to inhibit PTP activity in vitro noncompetitively, a mechanism involving oxidation of the catalytic cysteine residue. We investigated the pharmaceutical utility of this compound by examining its effects in a series of in vitro cellular and in vivo assays. Results showed that BVT.948 was able to enhance insulin signaling in cells, although it did not increase tyrosine phosphorylation globally. Furthermore, the compound was active in vivo, enhancing insulin tolerance tests in ob/ob mice, therefore apparently enhancing insulin sensitivity. BVT.948 was able to inhibit several other PTPs tested and also was efficient at inhibiting several cytochrome P450 (P450) isoforms in vitro. The data suggest that inhibitors of PTPs that display noncompetitive kinetics must be viewed with caution because they may oxidize the enzyme irreversibly. Furthermore, although such compounds display interesting biological effects in vitro and in vivo, their general pharmaceutical utility may be limited due to undesired effects on P450 enzymes.

Footnotes

  • DOI: 10.1124/jpet.103.062745.

  • ABBREVIATIONS. PTP, protein tyrosine phosphatase; BVT.948, 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione; pNPP, para-nitro phenylphosphate; OD, optical density; DTT, dithiothreitol; BVT.2274, 2,4-dihydroxy-3,3-dimethyl-2,3-dihydro-5H-benzo[g]indole-5-one-1-oxide; DMSO, dimethyl sulfoxide; α-MEM, minimum essential medium-α; P-Tyr, phosphorylated tyrosines; IR, insulin receptor; PBS, phosphate-buffered saline; P450, cytochrome P450; LAR, leukocyte antigen-related PTP; SHP-2, 5H2-containing PTP; TCPTP, T-cell PTP.

    • Received November 9, 2003.
    • Accepted January 22, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 309 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 309, Issue 2
1 May 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Oxidation of Protein Tyrosine Phosphatases as a Pharmaceutical Mechanism of Action: A Study Using 4-Hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

Oxidation of Protein Tyrosine Phosphatases as a Pharmaceutical Mechanism of Action: A Study Using 4-Hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione

Charlotta Liljebris, Pawel Baranczewski, Eva Björkstrand, Styrbjörn Byström, Bo Lundgren, Agneta Tjernberg, Malin Warolén and Stephen R. James
Journal of Pharmacology and Experimental Therapeutics May 1, 2004, 309 (2) 711-719; DOI: https://doi.org/10.1124/jpet.103.062745

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCELLULAR AND MOLECULAR

Oxidation of Protein Tyrosine Phosphatases as a Pharmaceutical Mechanism of Action: A Study Using 4-Hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione

Charlotta Liljebris, Pawel Baranczewski, Eva Björkstrand, Styrbjörn Byström, Bo Lundgren, Agneta Tjernberg, Malin Warolén and Stephen R. James
Journal of Pharmacology and Experimental Therapeutics May 1, 2004, 309 (2) 711-719; DOI: https://doi.org/10.1124/jpet.103.062745
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Comparison of piceatannol with resveratrol.
  • New PAS Repeat Sequence for Pharmacokinetic Enhancement
  • CD13 Promotes HCC Cell Chemoresistance
Show more Cellular and Molecular

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics